Lemtrada, a pharmaceutical drug approved to treat multiple sclerosis, has been linked to serious side effects that can result in permanent damage and death among New Jersey residents. Lemtrada causes arterial dissection (tears in the arterial lining of the head and neck) and stroke, caused by brain bleeding or lack of blood supply to the brain. Lemtrada stroke and artery tears are life-threatening events that kill brain cells and cause permanent brain damage. Lemtrada is already viewed as a risky treatment that should be used for MS patients in New Jersey only after other drugs fail; today, some safety experts believe the Lemtrada stroke risk tips the scales, such that Lemtrada side effects outweigh the drug's potential benefits.
A product of Genzyme, a subsidiary of the French pharmaceutical giant Sanofi, Lemtrada was approved in 2014 to treat relapsing forms of multiple sclerosis (MS) because it was found to offer better treatment outcomes over comparable drugs. At the same time, FDA safety experts were cautious about the risks posed by Lemtrada, ordering a comprehensive risk evaluation and mitigation strategy (REMS) to ensure serious Lemtrada risks be managed. Initial Lemtrada problems included anaphylactic responses and cancer; the danger of stroke from Lemtrada was only announced as a result of post-market adverse event reports to the FDA. In other words, MS patients, including residents of New Jersey, who have taken the drug since its release in 2014 were not warned about the Lemtrada stroke risk and were thus unknowingly exposed to a life-threatening complication. Annual sales of Lemtrada in the United States exceeded $275 million in 2017.
Now Sanofi Genzyme (the American division of the French pharmaceutical giant Sanofi) faces serious questions regarding Lemtrada side effects and early safety testing. Persons and the family members of persons who suffered from Lemtrada stroke in New Jersey are filing Lemtrada lawsuits against Genzyme. Filing a Lemtrada stroke lawsuit is the only means New Jersey individuals and families have to obtain the compensation they deserve for suffering, damage, medical expenses and loss related to Lemtrada stroke in New Jersey. In addition, filing a Lemtrada lawsuit claim is the best method for New Jersey consumers to hold Sanofi Genzyme executives accountable for the safety of this popular drug.
If you or a loved one suffered from arterial dissection or stroke from Lemtrada in New Jersey, you may eligible to file a Lemtrada stroke lawsuit against the manufacturer, Sanofi Genzyme. Lemtrada stroke lawsuits give New Jersey persons and families harmed by stroke or arterial dissection from this MS drug the means to seek compensation for the pain, suffering, and loss that has resulted.
In 2018, after four years on the market, Lemtrada was linked to the severe and life-threatening side effects of stroke and arterial dissection. Arterial dissection is a condition that causes tears to form in the linings of arteries in the head and neck. These artery tears can result in bleeding on the brain or a deprivation of blood flow to the brain, two different forms of stroke. While rare, Lemtrada stroke and arterial dissection are extremely serious and often result in permanent damage. For four years, patients in New Jersey took this medication with no knowledge of the risk for stroke; today, these New Jersey residents are seeking compensation through Lemtrada stroke lawsuits.
Most New Jersey families would prefer to not become involved in a lawsuit, but in the case of Lemtrada stroke, taking legal action is the only way to recover the compensation you deserve. Our experienced team of drug safety attorneys handling cases from New Jersey is available to assist you in learning about your legal rights and helping you take the simple steps to file a Lemtrada stroke lawsuit for yourself or a loved one in New Jersey. It is our belief that persons in New Jersey, having suffered from this severe condition with no prior warning of the risk, deserve and require compensation for the medical expenses, harm, and suffering resulting from Lemtrada stroke and arterial dissection in New Jersey - and we believe drug companies must be consistently held accountable for the safety of their products.
Our attorneys are now accepting New Jersey Lemtrada stroke claims for potential lawsuits and offer free, no-obligation Lemtrada lawsuit case review to anyone who suffered a stroke from Lemtrada in New Jersey. Stroke is a serious condition that can endanger a person's life and that frequently results in permanent damage and requires significant medical care. To discuss your situation with an attorney handling Lemtrada stroke lawsuits for New Jersey residents and to learn about Lemtrada lawsuit time limits in New Jersey, please complete our online contact form. One of our attorneys handling Lemtrada lawsuits for artery tears and stroke in New Jersey will contact you promptly.
Many people in New Jersey worry it may not be worthwhile to file a Lemtrada lawsuit related to stroke, fearing their story will become a number and a Lemtrada lawsuit will return only symbolic compensation. Lemtrada lawsuits for stroke and arterial dissection from New Jersey will not be class action lawsuits in which those who file a claim can expect only a small, symbolic settlement. Instead, attorneys for Lemtrada lawsuits believe New Jersey plaintiffs may be entitled to significant compensation.
Our attorneys representing New Jersey persons in Lemtrada stroke lawsuits assure clients that filing a claim is the only method to obtain the real compensation you deserve. Furthermore, filing a Lemtrada lawsuit is the only means for New Jersey residents to hold the drug company accountable for the safety of this drug. It is possible that individual Lemtrada lawsuits may be consolidated as Multi-District Litigation (MDL), a method where similar cases are grouped to accelerate the legal process while still preserving the unique facts and circumstances of each case. Whether your case is handled individually or joins forces in MDL, you can rest assured that compensation will be determined by the unique factors in each case and the degree of suffering encountered by each plaintiff.
We will represent all persons in New Jersey involved in a Lemtrada lawsuit for stroke or arterial dissection on a contingency basis, meaning our lawyers never charge legal fees unless we win compensation in your case. For a free no-obligation consultation please fill out our short online contact form and one of our attorneys for New Jersey Lemtrada stroke claims will contact you to answer any of your questions.
This page features answers to the most common questions we receive from New Jersey residents on filing a Lemtrada lawsuit for stroke or arterial dissection. Our team of lawyers handling Lemtrada lawsuits and New Jersey stroke claims provides free, no obligation case review to persons and family members of persons who have suffered from arterial dissection or stroke in New Jersey after taking Lemtrada. To discuss your situation and learn about your legal rights, contact our firm. One of our experienced lawyers for stroke lawsuits and New Jersey Lemtrada claims will contact you promptly to answer your questions, at no cost whatsoever.
The Lemtrada attorneys at The Onder Law Firm are known as national drug safety litigation leaders, having won large settlements against multinational pharmaceutical corporations on behalf of American consumers harmed by numerous dangerous drugs and medical devices. Armed with decades of expertise and a deep understanding of the pharmaceutical industry, our Lemtrada lawyers serving New Jersey residents specialize in helping consumers and their loved ones navigate the aftereffects of major drug recalls, achieving the significant compensation victims of drug safety lapses deserve. Aware of the very serious nature of New Jersey Lemtrada stroke claims, our firm has committed its substantial resources to providing clients in New Jersey with the best Lemtrada lawyer representation possible.
Our Lemtrada lawyers serving New Jersey residents believe persons and the loved ones of persons who have experienced arterial dissection or stroke in New Jersey as a result of Lemtrada may be entitled to significant compensation for the resultant harm and suffering. Filing a claim against Sanofi Genzyme is the only means to obtain compensation for medical bills from Lemtrada stroke in New Jersey. Lemtrada problems can result in life-threatening conditions and permanent brain damage.
It is the fervent belief of our Lemtrada stroke lawyers handling claims for New Jersey residents that pharmaceutical executives must be held accountable for the safety of their products and the damage caused by dangerous drugs. Working with a Lemtrada attorney to file a stroke claim in New Jersey is the best means for individual consumers to make their voices heard. It is an unfortunate fact that major litigation and the threat of large settlements is often required to prompt a pharmaceutical company into action to improve product safety. Our Lemtrada stroke lawyers for New Jersey plaintiffs see it as their mission to achieve justice and obtain the compensation our clients need and deserve, no matter how complex the case. To start a conversation about filing a claim, please contact our firm. Our Lemtrada stroke attorneys are now offering free case reviews to New Jersey persons and family members of persons who have suffered a stroke while taking Lemtrada in New Jersey.
We will represent all persons from New Jersey involved in a Lemtrada lawsuit on a contingency basis, meaning there are never any legal fees unless we win compensation in your case. Persons and loved ones of persons who have suffered a stroke while taking Lemtrada in New Jersey qualify for a free, no-obligation case review from our Lemtrada attorneys. Please complete the online contact form and a member of our Lemtrada stroke attorney team serving New Jersey will contact you promptly to discuss your case.
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation. For more information call 1-877-663-3752.